================================================================================


                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

                                  July 31, 2006
                Date of Report (Date of earliest event reported)

                    KIWA BIO-TECH PRODUCTS GROUP CORPORATION
             (Exact name of registrant as specified in its charter)


       DELAWARE                     000-33167                 84-0448400
(State or other jurisdiction      (Commission              (I.R.S. Employer
   of incorporation)              File Number)            Identification No.)

       415 WEST FOOTHILL BLVD, SUITE 206, CLAREMONT, CALIFORNIA 91711-2766
                    (Address of principal executive offices)

                                 (909) 626-2358
              (Registrant's telephone number, including area code)

                                       N/A
          (Former Name or Former Address, if changed since Last Report)

     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))


================================================================================


<PAGE>

ITEM  1.01 ENTRY INTO MATERIAL DEFINITIVE AGREEMENT

         On July 31, 2006,  we entered  into an  employment  agreement  with our
Chief Executive Officer, Wei Li, for a three-year term, commencing on January 1,
2006.  Pursuant to this  agreement,  Mr. Li will receive a salary at the rate of
RMB768,000  (approximately  $96,000) per annum, of which RMB600,000 will be paid
in equal  monthly  installments  of RMB50,000  during the period of  employment,
prorated for any partial  employment  period,  and RMB168,000 will be paid as an
annual performance bonus in three months after each employment year. Mr. Li will
receive  such annual  increases in salary as may be  determined  by our Board of
Directors at our annual  meeting.  Mr. Li is also entitled to an annual grant of
stock options under our employee stock option plan as determined by the Board of
Directors.  Mr. Li is entitled to  three-month's  severance if his employment is
terminated without cause. A copy of Mr. Li's employment agreement is attached as
Exhibit 10.1 to this report.

         On July 31, 2006,  we entered  into an  employment  agreement  with our
Chief  Financial  Officer,  Lianjun Luo, for a three-year  term,  commencing  on
January 1, 2006. Pursuant to this 2006 agreement,  we will pay Mr. Luo an annual
salary at the rate per annum of  RMB480,000  (approximately  $60,000),  of which
RMB384,000 will be paid in equal monthly  installments  of RMB32,000  during the
period of employment,  prorated for any partial employment period, and RMB96,000
will  be paid  as an  annual  performance  bonus  in  three  months  after  each
employment  year for the  successful  completion of all goals and  objectives of
that year and is entitled to an annual grant of stock options under our employee
stock option plan as determined  by the Board of Directors.  Mr. Luo is entitled
to three month's severance if his employment is terminated without cause. A copy
of Mr. Luo's employment agreement is attached as Exhibit 10.2 to this report.


ITEM  9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d)      Exhibits

EXHIBIT
NO.         DESCRIPTION

10.01 Employment  Agreement,  dated as of July 31, 2006,  between Kiwa  Bio-Tech
      Products Corporation and Wei Li

10.02 Employment  Agreement,  dated as of July 31, 2006,  between Kiwa  Bio-Tech
      Products Corporation and Lianjun Luo


                                       2
<PAGE>


                                    SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended,  the  Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.


Date: August 7, 2006

By:     /s/ Wei Li
        ----------------------------
Name:   Wei Li
Title:  Chairman of Board of Directors and Chief Executive Officer


                                       3
{"company-data": {"conformed-name": "KIWA BIO-TECH PRODUCTS GROUP CORP", "cik": "0001159275", "assigned-sic": "2870", "irs-number": "870448400", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "000-33167", "film-number": "061009407"}, "business-address": {"street1": "17700 CASTLETON STREET", "street2": "SUITE 589", "city": "CITY OF INDUSTRY", "state": "CA", "zip": "91748", "phone": "(626) 964-3232"}, "mail-address": {"street1": "17700 CASTLETON STREET", "street2": "SUITE 589", "city": "CITY OF INDUSTRY", "state": "CA", "zip": "91748"}, "former-company": {"former-conformed-name": "TINTIC GOLD MINING  CO", "date-changed": "20010918"}}
================================================================================

                UNITED STATES SECURITIES AND EXCHANGE COMMISSION
                             WASHINGTON, D.C. 20549

                                    FORM 8-K

                                 CURRENT REPORT
     PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934

                                  July 31, 2006
                Date of Report (Date of earliest event reported)

                    KIWA BIO-TECH PRODUCTS GROUP CORPORATION
             (Exact name of registrant as specified in its charter)

       DELAWARE                     000-33167                 84-0448400
(State or other jurisdiction      (Commission              (I.R.S. Employer
   of incorporation)              File Number)            Identification No.)

       415 WEST FOOTHILL BLVD, SUITE 206, CLAREMONT, CALIFORNIA 91711-2766
                    (Address of principal executive offices)

                                 (909) 626-2358
              (Registrant's telephone number, including area code)

                                       N/A
          (Former Name or Former Address, if changed since Last Report)

     Check the  appropriate  box below if the Form 8-K  filing  is  intended  to
simultaneously  satisfy the filing obligation of the registrant under any of the
following provisions:

|_|   Written communications pursuant to Rule 425 under the Securities Act (17
      CFR 230.425)

|_|   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)

|_|   Pre-commencement communications pursuant to Rule 14d-2(b) under the
      Exchange Act (17 CFR 240.14d-2(b))

|_|   Pre-commencement communications pursuant to Rule 13e-4(c) under the
      Exchange Act (17 CFR 240.13e-4(c))

================================================================================
ITEM  1.01 ENTRY INTO MATERIAL DEFINITIVE AGREEMENT

         On July 31, 2006,  we entered  into an  employment  agreement  with our
Chief Executive Officer, Wei Li, for a three-year term, commencing on January 1,
2006.  Pursuant to this  agreement,  Mr. Li will receive a salary at the rate of
RMB768,000  (approximately  $96,000) per annum, of which RMB600,000 will be paid
in equal  monthly  installments  of RMB50,000  during the period of  employment,
prorated for any partial  employment  period,  and RMB168,000 will be paid as an
annual performance bonus in three months after each employment year. Mr. Li will
receive  such annual  increases in salary as may be  determined  by our Board of
Directors at our annual  meeting.  Mr. Li is also entitled to an annual grant of
stock options under our employee stock option plan as determined by the Board of
Directors.  Mr. Li is entitled to  three-month's  severance if his employment is
terminated without cause. A copy of Mr. Li's employment agreement is attached as
Exhibit 10.1 to this report.

         On July 31, 2006,  we entered  into an  employment  agreement  with our
Chief  Financial  Officer,  Lianjun Luo, for a three-year  term,  commencing  on
January 1, 2006. Pursuant to this 2006 agreement,  we will pay Mr. Luo an annual
salary at the rate per annum of  RMB480,000  (approximately  $60,000),  of which
RMB384,000 will be paid in equal monthly  installments  of RMB32,000  during the
period of employment,  prorated for any partial employment period, and RMB96,000
will  be paid  as an  annual  performance  bonus  in  three  months  after  each
employment  year for the  successful  completion of all goals and  objectives of
that year and is entitled to an annual grant of stock options under our employee
stock option plan as determined  by the Board of Directors.  Mr. Luo is entitled
to three month's severance if his employment is terminated without cause. A copy
of Mr. Luo's employment agreement is attached as Exhibit 10.2 to this report.

ITEM  9.01 FINANCIAL STATEMENTS AND EXHIBITS

(d)      Exhibits

EXHIBIT
NO.         DESCRIPTION

10.01 Employment  Agreement,  dated as of July 31, 2006,  between Kiwa  Bio-Tech
      Products Corporation and Wei Li

10.02 Employment  Agreement,  dated as of July 31, 2006,  between Kiwa  Bio-Tech
      Products Corporation and Lianjun Luo

                                       2
SIGNATURE

         Pursuant to the requirements of the Securities Exchange Act of 1934, as
amended,  the  Registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.

Date: August 7, 2006

By:     /s/ Wei Li
        ----------------------------
Name:   Wei Li
Title:  Chairman of Board of Directors and Chief Executive Officer

                                       3